UK drug delivery device specialist Bespak on Wednesday reported near-triple full-year profits and said the outlook is rosy as it boosts production of the devices for Pfizer's inhaled insulin Exubera.
Bespak is one of two global producers of the Exubera device. Last month chief executive Mark Throdahl told APM the company had stepped up production to three shifts to meet orders and is shipping the devices to the U.S.
More.
Outlook rosy!? Let's see.
4 comments:
Hi Janet,
Have you found me yet over at www.diabetesmine.com?
Here's my take on Exubera: it is certainly not "a terrible idea." Rather, it is a potentially life-changing drug that's still under development. The "bong-like" delivery device certainly needs some work.
See http://www.diabetesmine.com/2006/06/exubera_bong_ok.html for more on that.
I dont know who Janet is, but if I meet her I'll pass on your kind message.
Cheers
Insider
No. Actually a fast acting insulin that can not give an accurate dose quickly is in fact "a terrible idea" unless you're the one selling it and not the one taking it.
Sure, anonymous, that's why it worked so well for the vast majority of those in the clinical trials for so many years, because they couldn't control the dose...
uh huh, sure.
It was so bad in fact, that when the trials ended, those using it begged to keep it. It must really suck and not work well, huh?
Post a Comment